Journal of Diabetes Research / 2015 / Article / Tab 3

Review Article

The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?

Table 3

Main characteristics of the DPP-4 inhibitors already approved for use in the US and/or EU market: sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin.

SitagliptinVildagliptinSaxagliptinAlogliptin Linagliptin

Dosing 100 mg qd50 mg bid5 mg qd25 mg qd5 mg qd

Max. DPP-4 inhibition (%)±97±9570–80>90>90

Selectivity for DPP-4HighHighModerateHighHigh

HbA1c reduction (%)0.5–1.00.9 (mean value)0.5–1.00.6 (mean value)0.5–0.7

Hypoglycaemic riskLowLowLowLowLow

Half-life compound (, h)±121.5–3±2.511–22>100

Bioavailability (%)±87±85±67±30

Renal excretion almost unchanged
(70–80% parent)
Renal excretion
(±26% parent and ±55% as metabolite obtained after hydrolysis)
Liver metabolized to active metabolite by P450 3A4/5 and renal excretion (12–29% unchanged parent and 21–52% as metabolite)Renal excretion almost unchanged parent (60–70%)Biliary excretion almost unchanged
(>70% unchanged parent) and renal (<6%)

Adapted from [9399] using available information/knowledge. HbA1c variations vary between studies and depend on baseline levels. Values presented are the range or mean value calculated from the studies available.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.